Press release
Steady Expansion Forecast for Bacterial Vaginosis Market, Projected to Reach $4.71 Billion by 2029
Bacterial Vaginosis
Bacterial Vaginosis Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
Regarding the bacterial vaginosis market, a significant upward trend in size has been observed over the last few years; projections indicate a rise from $3.03 billion in 2024 to $3.31 billion in 2025, reflecting a compound annual growth rate (CAGR) reaching 9.3%, with the preceding period's expansion being fueled by the broader uptake of at-home testing methods, the expansion of online retail, a surge in high-risk sexual practices, greater availability of vaccinations against sexually transmitted infections, and enhanced global access to medical care facilities.
Bacterial Vaginosis Market Size Forecast: What's the Projected Valuation by 2029?
Anticipation is high for substantial expansion within the bacterial vaginosis sector, projected to reach a valuation of $4.71 billion by 2029, driven by a compound annual growth rate (CAGR) of 9.2% across the coming years. This upward trajectory is fundamentally fueled by the escalating occurrence of bacterial vaginosis cases, mounting consumer desire for beneficial dietary products, a higher frequency of sexually transmitted infections (STIs), a greater recognition of various women's health issues, and heightened public consciousness regarding menopause. During this projection window, key shifts and innovations poised to shape the market include the incorporation of artificial intelligence (AI) techniques into diagnostic processes, increased utilization of probiotics, progress in at-home testing methodologies for STIs, and the utilization of environmentally conscious materials in products designed for women's well-being.
View the full report here:
https://www.thebusinessresearchcompany.com/report/bacterial-vaginosis-global-market-report
What Are the Drivers Transforming the Bacterial Vaginosis Market?
Elevated occurrences of infections transmitted through sexual contact are projected to fuel the expansion of the market for bacterial vaginosis. Infections transmitted sexually (STIs) designate ailments chiefly transmitted via intimate contact, which can stem from bacterial, viral, or parasitic origins. This surge in STI rates is attributable to elements like intercourse without protection, having numerous sexual partners, insufficient public knowledge, and resistance to antibiotics. Since bacterial vaginosis compromises the natural equilibrium of vaginal flora, it heightens vulnerability to STIs, thus easing the establishment of ailments such as HIV and chlamydia. To illustrate, data released in March 2024 by the European Centre for Disease Prevention and Control (ECDC), a governmental body established in Sweden, showed notable year-over-year escalations in documented cases during 2022, specifically a 48 percent jump in gonorrhea, a 34 percent rise in syphilis, and a 16 percent climb in chlamydia. Consequently, the escalating prevalence of sexually transmitted infections acts as a primary catalyst for the progression of the bacterial vaginosis market.
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21110&type=smp
What Long-Term Trends Will Define the Future of the Bacterial Vaginosis Market?
Leading firms within the bacterial vaginosis market are prioritizing the creation of novel diagnostic methods, such as employing multiplexed polymerase chain reaction (PCR) testing, aiming to expedite both the identification of the condition and subsequent patient management. A multiplexed PCR is characterized by its capability to facilitate the concurrent amplification and identification of several distinct DNA or RNA sequences within one PCR run. Illustratively, back in November 2022, Cepheid, an American biotechnology organization, launched its Xpert Xpress Multiplex Vaginal Panel (MVP); this innovative panel delivers diagnostic feedback in less than an hour, pinpointing three common vaginal ailments-bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and tricniasis (TV)-all evaluated from just one specimen. Furthermore, this technology accommodates samples collected either by a healare provider or through patient self-collection, utilizing automated real-time PCR to boost the precision of diagnoses and ultimately better the therapeutic results for female patients; its adaptable nature makes it viable across diverse clinical environments, guaranteeing swift and accurate identification of these vaginal infections.
Which Segments in the Bacterial Vaginosis Market Offer the Most Profit Potential?
The bacterial vaginosismarket covered in this report is segmented -
1) By Type: Point-Of-Care Testing; Laboratory Testing; Other Types
2) By Product: Below 15 Years; Between 15-45; Other Products
3) By Application: Antibiotics; Other Applications
4) By End-User: Hospitals; Homecare; Specialty Clinics; Other End Users
Subsegments:
1) By Point-Of-Care Testing: Rapid Diagnostic Tests; Microscopy-based Tests; Immunoassays
2) By Laboratory Testing: Gram Staining; Polymerase Chain Reaction (PCR); DNA Probe Tests; Culture-based Testing
3) By Other Types: Home Testing Kits; Enzyme-linked Immunosorbent Assay (ELISA)
Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=21110&type=smp
Which Firms Dominate the Bacterial Vaginosis Market by Market Share and Revenue in 2025?
Major companies operating in the bacterial vaginosis market are Pfizer Inc., Merck & Co. Inc., Merck KGaA, Bayer AG, Sanofi SA, Thermo Fisher Scientific, Becton inson, Viatris Inc., Otsuka Pharmaceutical, LabCorp, Quest Diagnostics, Organon & Co., UT Southwestern Medical Center, Hologic Inc., bioMérieux SA, Shionogi & Company Limited, Melinta Therapeutics Inc., Evofem Biosciences, Gedea Biotech, Fleurstat, Medical Diagnostic Laboratories
Which Regions Offer the Highest Growth Potential in the Bacterial Vaginosis Market?
North America was the largest region in the bacterial vaginosis market in 2024. The regions covered in the bacterial vaginosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21110
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Steady Expansion Forecast for Bacterial Vaginosis Market, Projected to Reach $4.71 Billion by 2029 here
News-ID: 4279381 • Views: …
More Releases from The Business Research Company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for Bacterial
Prominent Bacterial Conjunctivitis Market Trend for 2025: Innovative Eye Drops T …
What Are the Projected Growth and Market Size Trends for the Bacterial Conjunctivitis Market?
The bacterial conjunctivitis market has grown steadily, projected to expand from $4.52 billion in 2024 to $4.76 billion in 2025, at a CAGR of 5.3%. Growth factors include rising bacterial infection cases, improved diagnostics, patient education programs, stringent regulatory frameworks, and physician training.
The bacterial conjunctivitis market is projected to grow steadily, reaching $5.54 billion by 2029 at…
Community-Acquired Bacterial Pneumonia Market
DelveInsight's "Community-Acquired Bacterial Pneumonia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Community-Acquired Bacterial Pneumonia, historical and forecasted epidemiology as well as the Community-Acquired Bacterial Pneumonia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Community-Acquired Bacterial Pneumonia market report provides current treatment practices, emerging drugs, Community-Acquired Bacterial Pneumonia market share of the individual therapies, and current…
Bacterial Conjunctivitis Drugs Market Report 2018: Segmentation by Disease Type …
Global Bacterial Conjunctivitis Drugs market research report provides company profile for Pfizer Inc., Novartis AG, F. Hoffmann-La Roche, Bayer Healthcare, Valeant Pharmaceutical International Inc., Perrigo Company Plc, Akorn Inc., Santen Pharmaceutical Co. Ltd., Allergan Plc. and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth…
Bacterial Conjunctivitis Drugs Market: Rising Incidence of Ophthalmic Bacterial …
The U.S. market for bacterial conjunctivitis drugs has been declining sharply over the last few years. Analysts project the trend to continue in the coming years. In 2013, the market’s opportunity was valued at US$473.3 mn, which is likely to reduce to US$439.8 mn by 2024. In the coming years, the market will have to experience a patent cliff as the top U.S. brands of bacterial conjunctivitis drugs, such as…
Bacterial Conjunctivitis Drugs Market Driven by Rising Incidence of Ophthalmic B …
The U.S. market for bacterial conjunctivitis drugs is extremely fragmented, leading to commensurate competition among players. The entry barriers faced by new players despite having good research and development capabilities, is lack of capital, Transparency Market Research (TMR) states in its new report on the U.S. market for bacterial conjunctivitis drugs. R&D involves huge costs and this limits the production. Mergers and acquisitions and other forms of strategic alliances can…
Bacterial Conjunctivitis Drugs Market Driven by Rising Incidence of Ophthalmic B …
The U.S. market for bacterial conjunctivitis drugs has been declining sharply over the last few years. Analysts project the trend to continue in the coming years. In 2013, the market’s opportunity was valued at US$473.3 mn, which is likely to reduce to US$439.8 mn by 2024. In the coming years, the market will have to experience a patent cliff as the top U.S. brands of bacterial conjunctivitis drugs, such as…
